BDH Industries
BSE: BDH · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock BDH Industries's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
BDH Industries is a Mumbai-based pharmaceutical company specialising in the manufacturing and marketing of diverse therapeutic formulations. Its product portfolio spans oncology, cardiology, dermatology, and anti-infectives, supported by WHO-GMP certified manufacturing facilities.
Business Model
The company generates revenue through the production and sale of generic pharmaceutical formulations, serving both domestic Indian markets and international regions including Africa, Southeast Asia, and Latin America.
- Manufacturing Standards:WHO-GMP
Growth Outlook
Growth is driven by a focus on research and development to expand the generic drug pipeline and a strategic emphasis on providing affordable healthcare solutions in emerging markets.
Key Risks
- Regulatory Compliance. Failure to maintain international quality standards like WHO-GMP could result in the loss of export licences and market access.
- Currency Volatility. As a significant exporter to emerging markets, the company is exposed to fluctuations in foreign exchange rates that may impact profitability.
- Pricing Pressure. The generic pharmaceutical sector faces intense competition and government-mandated price controls, which can compress profit margins.
- Geopolitical Instability. Operations in emerging markets across Africa and Latin America are susceptible to political and economic instability that may disrupt supply chains.
Start your research today
Unlock AI insights, financials, peers and live data on BDH Industries and 5,000+ companies — free.
Key Metrics
REVENUE
₹0 Cr
TTM · standalone
NET PROFIT
₹11 Cr
TTM · standalone
EPS
₹18.78
TTM · standalone
RETURN ON EQUITY
21.9%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
29.1%
TTM · standalone
P/E
30.7x
Q4 FY26 · standalone
EV/EBITDA
13.8x
Q4 FY26 · standalone
EBITDA MARGIN
87.5%
TTM · standalone
NET PROFIT MARGIN
17.3%
Q3 FY25 · standalone
DEBT TO EQUITY
0.1x
Q3 FY25 · standalone
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
BDH IndustriesBDH | ₹296 Cr | 27.33 | 18.45 | -100.0% | 87.5% | 21.9% | 29.1% | +56.8% |
Albert DavidALBERTDAVD | ₹513 Cr | 22.73 | 13.48 | 11.4% | 11.0% | 5.8% | 7.5% | +12.1% |
Jenburkt Pharmaceuticals LimitedJENBURPH | ₹463 Cr | 13.31 | 8.46 | — | 32.0% | 17.6% | 23.2% | -4.3% |
Haleos Labs LimitedHALEOSLABS | ₹452 Cr | 28.60 | 12.72 | -3.1% | 13.6% | 7.4% | 10.3% | — |
TranschemTRANSCHEM | ₹424 Cr | 98.76 | 68.07 | -100.0% | 177.7% | 5.3% | 7.0% | +592.6% |
Medicamen BiotecMEDICAMEQ | ₹338 Cr | 33.59 | 15.53 | 24.7% | 11.3% | 4.1% | 6.2% | -27.9% |
As of Q4 FY26
Financials
BDH Industries
BSE: BDH · Pharmaceuticals
Limited coverage
We are not actively covering this company or have limited coverage today. Click to request coverage.
Snapshot
Unlock BDH Industries's vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
BDH Industries is a Mumbai-based pharmaceutical company specialising in the manufacturing and marketing of diverse therapeutic formulations. Its product portfolio spans oncology, cardiology, dermatology, and anti-infectives, supported by WHO-GMP certified manufacturing facilities.
Business Model
The company generates revenue through the production and sale of generic pharmaceutical formulations, serving both domestic Indian markets and international regions including Africa, Southeast Asia, and Latin America.
- Manufacturing Standards:WHO-GMP
Growth Outlook
Growth is driven by a focus on research and development to expand the generic drug pipeline and a strategic emphasis on providing affordable healthcare solutions in emerging markets.
Key Risks
- Regulatory Compliance. Failure to maintain international quality standards like WHO-GMP could result in the loss of export licences and market access.
- Currency Volatility. As a significant exporter to emerging markets, the company is exposed to fluctuations in foreign exchange rates that may impact profitability.
- Pricing Pressure. The generic pharmaceutical sector faces intense competition and government-mandated price controls, which can compress profit margins.
- Geopolitical Instability. Operations in emerging markets across Africa and Latin America are susceptible to political and economic instability that may disrupt supply chains.
Start your research today
Unlock AI insights, financials, peers and live data on BDH Industries and 5,000+ companies — free.
Key Metrics
REVENUE
₹0 Cr
TTM · standalone
NET PROFIT
₹11 Cr
TTM · standalone
EPS
₹18.78
TTM · standalone
RETURN ON EQUITY
21.9%
TTM · standalone
RETURN ON CAPITAL EMPLOYED
29.1%
TTM · standalone
P/E
30.7x
Q4 FY26 · standalone
EV/EBITDA
13.8x
Q4 FY26 · standalone
EBITDA MARGIN
87.5%
TTM · standalone
NET PROFIT MARGIN
17.3%
Q3 FY25 · standalone
DEBT TO EQUITY
0.1x
Q3 FY25 · standalone
Peers · Pharmaceuticals
As of Q4 FY26